Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome
Rhea-AI Summary
Quoin Pharmaceuticals (NASDAQ: QNRX) announced the FDA granted Fast Track Designation to QRX003 lotion (4%) for treatment of Netherton Syndrome on March 11, 2026. QRX003 is in two late-stage whole-body clinical trials and previously received Orphan Drug and Pediatric Rare Disease designations from FDA and EMA.
The Fast Track status enables more frequent FDA interactions and potential accelerated review pathways that may speed development toward a first approved therapy for this rare disorder.
Positive
- FDA Fast Track Designation granted for QRX003 (4%)
- QRX003 is in two late-stage whole-body clinical trials
- Prior Orphan Drug and Pediatric Rare Disease designations from FDA and EMA
Negative
- No approved treatments exist for Netherton Syndrome; QRX003 remains investigational
- Press release provides no disclosed efficacy or timeline data from the late-stage trials
News Market Reaction – QNRX
On the day this news was published, QNRX declined 1.13%, reflecting a mild negative market reaction. Argus tracked a peak move of +6.7% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $159K from the company's valuation, bringing the market cap to $14M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Ahead of the Fast Track news, QNRX was up 1.87% while momentum peers showed mixed moves: OGEN up ~4.93%, AZTR and PALI down. This points more to stock-specific drivers than a uniform sector move.
Previous Clinical trial,fda approval Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 21 | FDA orphan designation | Positive | -1.2% | U.S. FDA granted Orphan Drug Designation for QRX003 in Netherton Syndrome. |
| May 22 | FDA trial clearance | Positive | +0.0% | FDA clearance to initiate second pivotal whole-body QRX003 Netherton study. |
| Dec 19 | New clinical study OK | Positive | +15.0% | FDA clearance for new QRX003 whole-body clinical study in Netherton Syndrome. |
Regulatory and clinical milestones for QRX003 have generally been viewed positively but with mixed immediate price reactions, including both modest declines and double-digit gains.
Recent history centers on QRX003’s path through regulatory and clinical milestones. Prior FDA clearance and designation news on Dec 19, 2024, May 22, 2025, and Oct 21, 2025 drove 24-hour moves ranging from -1.16% to +14.99%. These events involved FDA clearances to initiate QRX003 studies and an Orphan Drug Designation, with timelines pointing toward NDA filings. Today’s Fast Track Designation extends this theme of progressive regulatory de‑risking for the same asset.
Historical Comparison
Past QRX003 FDA/clinical milestones with this tag saw an average 4.61% 24-hour move, with reactions ranging from slightly negative to strong double-digit gains.
The same-tag history shows stepwise progress: initial FDA clearances for QRX003 studies, followed by Orphan Drug Designation, and now Fast Track status for Netherton Syndrome.
Regulatory & Risk Context
An effective Form S-3 covers resale of up to 10,045,455 ADSs by selling shareholders; Quoin will not receive proceeds from resales but could receive up to $88.7 million if related warrants are exercised for cash. The filing highlights potential dilution, with ADSs covered approximately 1,193% of ADSs outstanding as of November 3, 2025.
Market Pulse Summary
This announcement adds FDA Fast Track Designation for QRX003 to an existing suite of benefits, including U.S. and EU Orphan Drug and Pediatric Rare Disease designations, all in a disease with no approved treatments. Historical news shows stepwise regulatory progress for QRX003 with varied short-term price reactions. Investors may track upcoming late-stage trial readouts, regulatory filing timelines, and potential dilution from the registered 10,045,455 ADSs under the S-3.
Key Terms
fast track designation regulatory
orphan drug designation regulatory
pediatric rare disease designation regulatory
european medicines agency regulatory
clinical trials technical
netherton syndrome medical
AI-generated analysis. Not financial advice.
— Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need —
— QRX003 lotion (
— Fast Track Designation follows Pediatric Rare Disease and Orphan Drug Designation previously granted by the FDA and Orphan Drug Designation granted by the European Medicines Agency for QRX003 in Netherton Syndrome —
ASHBURN, Va., March 11, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 lotion (
"We believe that the FDA's decision to grant Fast Track Designation to QRX003 reflects the urgent unmet need faced by patients and families living with Netherton Syndrome," said Dr. Michael Myers, CEO and Co-Founder of Quoin Pharmaceuticals. "Fast Track status enables more frequent communication with the FDA and the potential for accelerated regulatory review pathways, which may help bring the first approved treatment for Netherton Syndrome to patients as quickly as possible."
QRX003 Development Program
QRX003 lotion (
QRX003 previously received Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency (EMA) for the treatment of Netherton Syndrome, providing potential benefits including market exclusivity upon approval, tax credits for clinical testing, and certain regulatory fee reductions. QRX003 has also been granted Pediatric Rare Disease Designation by the FDA.
About Netherton Syndrome
Netherton Syndrome is a rare, inherited skin disorder caused by mutations in the SPINK5 gene, leading to severe skin barrier dysfunction, chronic inflammation, and a heightened risk of infections and allergic complications. Patients often experience widespread skin redness, scaling, persistent itching, and significant impairment in quality of life. There are currently no FDA-approved therapies for the treatment of Netherton Syndrome, and treatment options are limited to supportive care and off-label therapies.
About Fast Track Designation
The FDA's Fast Track program is designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need. A therapy granted Fast Track Designation may benefit from more frequent interactions with the FDA, eligibility for rolling review of regulatory submissions, and potential qualification for Accelerated Approval and Priority Review, if relevant criteria are met.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises several products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
Cautionary Note Regarding Forward Looking Statements
The Company cautions that statements in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” “look forward to,” and “will,” among others. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: the potential for an accelerated regulatory review pathway for QRX003, bringing the first approved treatment for Netherton Syndrome to patients as quickly as possible, timing of clinical studies, and Quoin’s products in development collectively having the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company’s ability to pursue its regulatory strategy; the Company’s ability to obtain regulatory approvals for the commercialization of product candidates or to comply with ongoing regulatory requirements; the Company’s ability to complete clinical trials on time and achieve desired results and benefits as expected; and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
For further information, contact:
Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO
mmyers@quoinpharma.com
Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341
FAQ
What does FDA Fast Track Designation for QRX003 mean for QNRX and patients?
What stage are QRX003 clinical trials for Netherton Syndrome (QNRX) in as of March 11, 2026?
What other regulatory designations has QRX003 received prior to the Fast Track (QNRX)?
Does Fast Track guarantee QRX003 will be approved for Netherton Syndrome (QNRX)?
How might Fast Track affect QNRX's regulatory timeline for QRX003 after March 11, 2026?
